In this solemn time due to the coronavirus pandemic, each country is trying hard to develop the first COVID-19 vaccine. According to some sources India is likely to get the first Oxford-AstraZenenca vaccine for COVID-19 after it gets all required clearances. India is expecting to get this vaccine by the end of this year. Other local vaccines are also being developed to enter into the human Phase trials, and are expected to be entered in the market after the gap of a few weeks.
Oxford Vaccine is ahead of the two other Vaccines being manufactured
Oxford candidates are being manufactured in the Pune-based serum institute of India who had collaborated with pharma giant AstraZeneca for manufacturing certain vaccines for the Covid-19 pandemic. Oxford Candidates are ahead of the other two vaccines, which have entered in the different stages of human phase trials. A source has said that if this vaccine gets the trail and is being produced in India, is certainly reliable to be used.
Oxford-AstraZeneca vaccine has entered in Advance Stages
Bharat Biotech’s Covaxin is being jointly developed with ICMR is in early phases 1 and 2, with Zydus Cadila’s Zycov D vaccine. Whereas, the Serum has already begun the advanced phases of human trials in India with over 1600 citizens, aged above 18, in 17 chosen sites in the entire country. Around 1,000 to 1,100 participants have enrolled in 5 to 8 sites for the trials, said the report.
Oxford vaccine has scored better than the other vaccines being developed outside India, it has shown comparatively better results for being manufactured in SII, the serum institute of India.
Last week on 11 August, CEO of SII Adar Poonawalla has announced that India will have the vaccine against coronavirus by the end of September and however disclosed the proposed price of the vaccine. He further added that the final price of the vaccine will be declared within two months after the vaccine gets all required rounds clear as well as is approved.
SII has targeted to manufacture 100 million doses of vaccine
Pune-based the serum institute of India has targeted to produce around 100 million doses of the vaccine and will deliver them in the low and middle-income countries along with India.